Replies to post #36969 on Ayala Pharmaceuticals Inc (ADXS)

[Gantor50]

Your cash burn projections once again make me wonder what DOC was thinking. He had between $140M and $160M a year ago. And he proceeded to get even more aggressive in his spending.

I had always assumed he would use that position of strength to drive a major partner deal for Euro rights. I don't know if his plan was always going to be another secondary, but then he got boxed out when the PPS dropped into the cellar or what. But then if he believe his PPS was going to be his currency, why didn't he do more to protect it?

I know it's easy to just pile on and call him names, but I would seriously like to know what his plan was, even if it obviously didn't happen the way he might have imagined 12 months ago. You negotiate from strength, not from weakness. DOC had to know that. So why? Just musing.

[James salmon]

What about Amgen milestone payment for start of NEO,this will bring in some revenue.

[fbg0316]

Meish, as I recall you are a relatively new investor. To give you some sense of what long-term shareholders have been through, when O'Connor came on board fully diluted total shares outstanding was around 25 million, so a $40 share price equated to a $1 billion valuation. Fast forward to now (four years later) the fully diluted total shares outstanding is around 50 million, so a $20 share price now equates to a $1 billion valuation. I understand some dilution has been necessary, but whose to say kicking the can down the road another four years and there is another 25 million shares sold, then what do you know a $13 stock price is a $1 billion valuation. I know you are looking at things prospectively and the timing of your investment is certainly much better than mine, but one needs to look at the track record of the company's execution, inefficient use of funds and lack of shareholder value generated on capital already raised, which leads me to my belief that shareholders would likely be better off if the company is outright sold today instead of risking more dilution at a low stock price and more potential execution mis-steps toward commercialization.

[jckrdu]

Good thoughts. I'm pretty much aligned with your thinking. While all of us want no further dilution, if ADXS can announce some good news and then raise capital at a much higher pps than current levels - via a moderate sized offering (20% dilution max) - that may be the best way to increase shareholder value for the long-term.

I've seen other companies rally after moderate sized offerings that are done on the back-end of good news and a higher pps, which then takes the fear of low-ball dilution off the table... and the market starts looking to the future.

We'll see how Lombardo plays it. Best case scenario is obviously a fat licensing deal for HER2, but we'll see if that's in the cards.

[Easymoneyman00]

Not going o dilute that much sorry! Trial news is everything and at this time not much is being said. So we will wait and see where we go when more trial news is released.